You are here: Industry Insights > Migraine

News List

Eli Lilly files for FDA approval of migraine drug lasmiditan fiercebiotech
November 15, 2018
Eli Lilly has filed for FDA approval of migraine drug lasmiditan. The Big Pharma is seeking approval of the 5-HT1F agonist on the strength of late-phase data showing the drug clears headache pain in two hours in some patients.
US regulator approves Teva's migraine drug biospectrumasia
September 29, 2018
Teva's drug can also be given in three-month intervals in three consecutive injections
Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP fiercepharma
September 29, 2018
Lilly will provide 12 months of Emgality to patients for free under an access program, an executive said. (Eli Lilly)
Lilly’s Emgality wins first nod for migraine prevention pharmatimes
September 29, 2018
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Emgality Receives FDA Approval for the Preventive Treatment of Migraine americanpharmaceuticalreview
September 29, 2018
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.
Teva’s anti-CGRP drug Ajovy cleared for migraine prevention pharmatimes
September 18, 2018
US regulators have approved Teva’s Ajovy for the preventative treatment of migraine in adults.
A new era for migraine patients cphi-online
August 07, 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.
Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals? fiercepharma
July 30, 2018
Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that by handing out a lot of the product for free.
Amgen, Novartis’ migraine therapy impresses again pharmatimes
July 16, 2018
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
Allergan’s experimental migraine drug hits trial targets pharmatimes
July 10, 2018
Allergan says its CGRP receptor antagonist atogepant has hit its primary target in a Phase IIb/III trial assessing its efficacy in preventing episodic migraine.

Previous page 1 2 3 4 5 6 7 8 9 Next page